Key Highlights
- Raymond W. Cohen, seasoned medtech leader, joins Kestra’s board.
- Kestra closed $196M funding for commercial expansion.
- CEO Brian Webster praises Cohen’s strategic experience.
- Cohen’s history with Axonics and other medtech firms enhances Kestra’s potential.
Source: Business Wire
Notable Quotes
- “Ray is one of the most experienced and accomplished leaders in the medical device industry with multiple decades of success in developing and commercializing emerging medical technologies.” — Brian Webster, President & CEO at Kestra
- “Kestra has a world-class wearable defibrillator product and is poised to compete aggressively in this former monopoly market which is estimated to be in the $1B revenue range.” — Raymond W. Cohen, CEO and Board Member at Axonics Inc
SoHC's Take
Raymond W. Cohen’s addition to Kestra Medical Technologies’ board is a strategic move that underscores Kestra’s commitment to advancing its position in the wearable cardioverter defibrillator (WCD) market. Cohen’s extensive experience in the medtech industry, particularly with the successful growth and eventual acquisition of Axonics, will be invaluable to Kestra. His proven track record in guiding companies through strategic exits and IPOs is expected to provide significant benefits to Kestra’s stakeholders. This appointment, coupled with the recent $196 million funding round, positions Kestra for robust growth and market leadership in the wearable medical device sector.
